Corticobasal Degeneration (CBD)
Because there is no specific therapy designed to alleviate the underlying processes of the disease, the treatment of corticobasal degeneration (CBD) remains a daunting challenge. Protheragen strives to solve the problem of CBD management through innovative diagnostic and therapeutic development. As a trusted collaborator in therapeutic research for CBD, we offer all-inclusive and top-quality service packages tailored to fulfill diverse scientific research requirements.
Overview of Corticobasal Degeneration (CBD)
Corticobasal degeneration (CBD) is neurodegenerative disorder that is classified among the rare tauopathies. It is characterized by the excessive accumulation of hyperphosphorylated tau protein in neurons and glial cells. With an estimated prevalence of 4.9-7.3 cases per 100,000, CBD presents a significant diagnostic and therapeutic challenge due to its clinical overlap with Parkinson's disease (PD), progressive supranuclear palsy (PSP), and frontotemporal dementia (FTD).
Fig.1 Macroscopic and microscopic findings of patients with CBS and underlying pathology of CBD (A–E), PSP (F–J), and AD (K–O). (Koga S, et al., 2022)
Pathogenesis of Corticobasal Degeneration (CBD)
Corticobasal degeneration (CBD) is caused by the aggregation of 4-repeat (4R) tau protein isoforms which leads to severe neuronal and glial inclusions involving the frontoparietal cortices and basal ganglia. The MAPT H1 haplotype provides some genetic risk which causes tauopathies with disruption of microtubule and axonal transport systems, resulting in neurodegeneration. Other contributory factors include the spread of tau pathologies in a prion-like fashion and neuroinflammation mediated by activated microglia. Neuronal vulnerability is also exacerbated by mitochondrial dysfunctions and oxidative stress.
Fig.2 Unpicking corticobasal syndrome and corticobasal degeneration. (Wilson D, et al., 2021)
Therapeutic Development for Corticobasal Degeneration (CBD)
| Drug Name | Mechanism of Action | Targets | NCT Number | Research Phase |
| Glycerol Phenylbutyrate (GPB) | Lowers ammonia levels by providing alternative nitrogen excretion pathway | Hepatic urea cycle enzymes | NCT05983588 | Phase II |
| Apomorphine | Dopamine D1/D2 receptor agonist to address parkinsonism | Striatal dopamine receptors | NCT04786158 | Phase IV |
Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
Our Services
Protheragen specializes in comprehensive corticobasal degeneration (CBD) solutions, developing diagnostic biomarkers for early detection and targeted therapeutics addressing tau pathology. Our platform utilizes advanced disease models, including transgenic systems and iPSC-derived neurons, coupled with proprietary blood-brain barrier (BBB) evaluation to optimize CNS drug development for CBD and related tauopathies.
Therapeutic Development Services
By Molecule Types
At Protheragen, we have established comprehensive molecular platforms for therapeutic development of corticobasal degeneration (CBD), including monoclonal antibodies targeting tau, small molecule tau aggregation inhibitors, MAPT gene therapy, etc.
By Mechanism of Action
Focusing on the development of personalized therapies for corticobasal degeneration (CBD), Protheragen designs compounds targeting neurodegenerative pathological mechanisms to facilitate effective management of CBD.
Disease Model Development Services
In Vitro Model
Development
Development
- Tau Overexpression Model: Engineered to overexpress human 4-repeat tau isoforms with mutations like P301L or R406W to induce neurofibrillary tangles and astrocytic plaques.
- MAPT H1 Haplotype Model: CRISPR-modified rodents carrying the H1 tau haplotype, a major genetic risk factor for CBD, to study disease susceptibility.
At Protheragen, we provide advanced microfluidic models of corticobasal degeneration (CBD) to recapitulate human-specific tau pathology and neuro-glia interactions. Specializing in comprehensive preclinical assessment, our company offers professional pharmacodynamic (PD), pharmacokinetic (PK) and toxicology research services to accelerate the therapeutic development of CBD. If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
References
- Koga S, Josephs K A, Aiba I, et al. Neuropathology and emerging biomarkers in corticobasal syndrome[J]. Journal of Neurology, Neurosurgery & Psychiatry, 2022, 93(9): 919-929.
- Wilson D, Le Heron C, Anderson T. Corticobasal syndrome: a practical guide[J]. Practical Neurology, 2021, 21(4): 276-285.